1. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination;Lucchinetti;Ann. Neurol.,2000
2. F.D. Lublin, S.C. Reingold, J.A. Cohen, G.R. Cutter, P.S. Sorensen, A.J. Thompson, J.S. Wolinsky, L.J. Balcer, B. Banwell, F. Barkhof, B. Bebo, P.A. Calabresi, M. Clanet, G. Comi, R.J. Fox, M.S. Freedman, A.D. Goodman, M. Inglese, L. Kappos, B.C. Kieseier, J. A. Lincoln, C. Lubetzki, A.E. Miller, X. Montalban, P.W. O'Connor, J. Petkau, C. Pozzilli, R.A. Rudick, M.P. Sormani, O. Stuve, E. Waubant, C.H. Polman, Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83 (2014) 278–286.
3. MRI as a marker for disease heterogeneity in multiple sclerosis;Bielekova;Neurology,2005
4. The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain;Haider;Brain,2016
5. Inflammatory demyelination and neurodegeneration in early multiple sclerosis;Charil;J. Neurol. Sci.,2007